Ceftriaxone

Generic Name: Ceftriaxone

Brand Names: Rocephin

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₈N_₈O_₇S_₃

CAS Number: 73384-59-5

Unique Ingredient Identifier: 75J73V1629

Background: Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.

Indication: Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.

Associated Conditions: Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial

Clinical Trials

Zoliflodacin in Uncomplicated Gonorrhoea

Phase 3

Completed

Conditions: Gonorrhea

Interventions: Drug: zoliflodacin
Drug: ceftriaxone
Drug: azithromycin

First Posted Date: 2019-05-22

Last Posted Date: 2024-07-26

Lead Sponsor: Global Antibiotics Research and Development Partnership

Target Recruit Count: 1011

Registration Number: NCT03959527

Locations: 🇺🇸
Public Health - Seattle & King County STD Clinic, Seattle, Washington, United States
🇺🇸
Jefferson County Department of Health, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 14 locations

Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection.

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
Drug: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
Drug: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)

First Posted Date: 2019-03-29

Last Posted Date: 2025-02-25

Lead Sponsor: University of Oxford

Target Recruit Count: 37

Registration Number: NCT03895567

Locations: 🇹🇭
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Experimental Human Infection With Neisseria Gonorrhoeae

Phase 1

Completed

Conditions: Gonococcal Infection

Interventions: Drug: Cefixime
Drug: Ceftriaxone
Drug: Ciprofloxacin
Biological: Neisseria gonorrhoeae strain FA7537
Biological: Neisseria gonorrhoeae strain FA1090 A26

First Posted Date: 2019-02-15

Last Posted Date: 2021-03-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT03840811

Locations: 🇺🇸
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States

Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis
Inflammatory Bowel Diseases
Acute Severe Colitis

Interventions: Other: Placebo infusion
Drug: Ceftriaxone
Drug: Metronidazole

First Posted Date: 2019-01-07

Last Posted Date: 2020-12-11

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 50

Registration Number: NCT03794765

Locations: 🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India

Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis

Phase 2

Completed

Conditions: Infectious Endocarditis

Interventions: Drug: Ceftriaxone 4g/ 24h
Drug: Ceftriaxone 2g/ 12h

First Posted Date: 2018-09-24

Last Posted Date: 2024-04-03

Lead Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Target Recruit Count: 12

Registration Number: NCT03681431

Locations: 🇪🇸
University Hospital Virgen del Rocio, Sevilla, Spain

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

Phase 4

Terminated

Conditions: Post-Op Wound Infection
Open Fracture

Interventions: Drug: Clindamycin + Gentamicin
Drug: Cefazolin + Gentamicin
Drug: Piperacillin/tazobactam
Drug: Ampicillin/sulbactam
Drug: Ceftriaxone

First Posted Date: 2018-06-18

Last Posted Date: 2020-09-11

Lead Sponsor: Mercy Health Ohio

Target Recruit Count: 17

Registration Number: NCT03560232

Locations: 🇺🇸
St. Joseph Warren Hospital, Warren, Ohio, United States
🇺🇸
St. Elizabeth Youngstown Hospital, Youngstown, Ohio, United States

Penile Fracture: A Comparison of Erectile Function After Immediate Repair Versus Delayed Repair

Not Applicable

Completed

Conditions: Erectile Dysfunction

Interventions: Procedure: Immediate repair
Procedure: Delayed repair
Drug: Ceftriaxone
Drug: Lidocaine
Drug: Diclofenac Sodium

First Posted Date: 2018-02-28

Last Posted Date: 2018-03-01

Lead Sponsor: Ministry of Health, Jamaica

Target Recruit Count: 46

Registration Number: NCT03449940

Locations: 🇯🇲
Kingston Public Hospital, Kingston, Jamaica
🇯🇲
University Hospital of the West Indies, Kingston, Jamaica

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

Phase 2

Active, not recruiting

Conditions: Parkinson's Disease Dementia

Interventions: Other: Placebo
Drug: Ceftriaxone

First Posted Date: 2018-01-29

Last Posted Date: 2025-02-05

Lead Sponsor: BrainX Corporation

Target Recruit Count: 100

Registration Number: NCT03413384

Locations: 🇨🇳
Changhua Christian Hospital, Changhua, Taiwan
🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
🇨🇳
Chung Shan Medical University Hospital, Taichung, Taiwan

and more 3 locations